ライフサイエンスコーパス: megestrol

1 or evidence for a causal relationship (e.g., megestrol); (2) drugs without prior evidence for a causa

2 ause of toxicity and/or patient refusal than megestrol acetate (36% v 25%; P =.03).

3 sponse rates in breast cancer with high-dose megestrol acetate (MA) 800 mg/d, this phase II trial ass

4 This study tests the progestin megestrol acetate (MA) at two doses versus placebo over

5 utethimide (AG) and hydrocortisone (HC) plus megestrol acetate (MA) improved response rates, response

6 an EPA supplement-administered alone or with megestrol acetate (MA)-was more effective than MA.

7 to receive either dexamethasone 0.75 mg qid, megestrol acetate 800 mg orally every day, or fluoxymest

8 cancer patients were randomized to (1) oral megestrol acetate 800 mg/d liquid suspension plus placeb

9 Patients were randomized to receive megestrol acetate 800 mg/d orally or placebo.

10 ferences in appetite or weight compared with megestrol acetate alone.

11 ], 0.75 to 1.24) for anastrozole 1 mg versus megestrol acetate and 0.92 (97.5% CI, 0.71 to 1.19) for

12 Megestrol acetate and dexamethasone caused a similar deg

13 hoice for treating cancer anorexia/cachexia, megestrol acetate and dexamethasone have similar appetit

14 owth hormone, testosterone, oxandrolone, and megestrol acetate and emerging data on the orexigenic pe

15 ential of combining natural supplements with megestrol acetate and found that the addition of the nat

16 relevant benefit, letrozole is equivalent to megestrol acetate and should be considered for use as an

17 The role of the progestin megestrol acetate and, paradoxically, of tamoxifen in th

18 eneration aromatase inhibitors have replaced megestrol acetate as second-line hormonal therapy in rec

19 e first time that the anti-tumor activity of megestrol acetate can be enhanced by combining with pter

20 Megestrol acetate cannot be routinely recommended for al

21 e potential application of pterostilbene and megestrol acetate combination for the treatment of endom

22 Patients who received megestrol acetate continued to gain weight over time.

23 status, with nonsignificant trends favoring megestrol acetate for both of these parameters.

24 nfluenced by a poorer quality of life of the megestrol acetate group at study initiation.

25 nastrozole 10-mg group, and 20 (7.9%) in the megestrol acetate group had a complete or partial respon

26 P < .002) groups had weight gain than in the megestrol acetate group.

27 patients in the anastrozole groups than the megestrol acetate group; the difference between the anas

28 difference between the anastrozole 10 mg and megestrol acetate groups was significant (P = .005).

29 Megestrol acetate had a higher rate of deep venous throm

30 Those who received megestrol acetate had increased nonfluid weight gain (P

31 Patients who received megestrol acetate had more edema (30% v 20%, P = .002),

32 Megestrol acetate has been reported to improve appetite

33 To enhance the activity of megestrol acetate in endometrial cancer patients, we exp

34 daily, is well tolerated and as effective as megestrol acetate in the treatment of postmenopausal wom

35 Megestrol acetate is a frequently used drug in endometri

36 ial was formulated to evaluate the impact of megestrol acetate on quality of life, toxicity, response

37 eive second-line hormone therapy with either megestrol acetate or an aromatase inhibitor (fadrozole o

38 In the doses and schedules we studied, megestrol acetate provided superior anorexia palliation

39 natural phenolic compound, pterostilbene, to megestrol acetate resulted in a synergistic inhibition o

40 erapy avoids the weight gain associated with megestrol acetate treatment.

41 occurred more often in patients who received megestrol acetate versus placebo (9% v 2%, P = .01).

42 Megestrol acetate was more likely to produce weight gain

43 Anastrozole and megestrol acetate were well tolerated.

44 h-dose progestin treatment of breast cancer (megestrol acetate) also increase VEGF in the media of cu

45 steroids (eg, growth hormone, testosterone, megestrol acetate) in malnutrition and other catabolic s

46 (progesterone, medroxyprogesterone acetate, megestrol acetate, mifepristone, pregnanediol, 17alpha-h

47 double-blind for anastrozole, open-label for megestrol acetate, parallel-group, multicenter trials we

48 rel, cyproterone acetate, norethindrone, and megestrol acetate, were found to be only weak stimulator

49 n improvement in quality of life (QOL) among megestrol acetate-treated and combination-treated patien

50 More than 30% of megestrol acetate-treated patients had weight gain > or

51 A greater percentage of megestrol acetate-treated patients reported appetite imp

52 ncidence of impotence among men who received megestrol acetate.

53 053) for survival benefit when compared with megestrol acetate.

54 =.018), compared with patients treated with megestrol acetate.

55 gens, including flutamide, bicalutamide, and megestrol acetate.

56 , 0.71 to 1.19) for anastrozole 10 mg versus megestrol acetate.

57 sease with botulinum toxin; weight loss with megestrol acetate; and sialorrhea with glycopyrollate.

58 s, progesterone, desogestrel, norethindrone, megestrol, algestone, norprogesterones, and levonorgestr

59 A variety of regimens, including megestrol, bicalutamide, glucocorticoids, aminoglutethim